TLDR
- PAHC drops 4.67% after CEO share sale filing sparks fresh market attention today
- Phibro stock reverses early rally as SEC filing reveals insider share sales
- PAHC falls sharply while strong earnings growth remains part of the backdrop
- CEO’s indirect sale of 21,120 shares puts Phibro stock under pressure
- Raised 2026 guidance stays in focus as PAHC shares retreat on Tuesday
Phibro Animal Health Corporation (PAHC) shares fell sharply on Tuesday, with PAHC trading at $53.51, down 4.67%. Earlier, the stock surged near $56.60 before reversing lower during active trading. It later recovered from lows below $52, yet remained under morning resistance levels.
Phibro Animal Health Corporation, PAHC
The decline followed a new SEC filing that disclosed insider stock sales by Chief Executive Officer Jack Bendheim. The filing showed multiple transactions completed between April 21 and April 23, 2026. Markets often react quickly when executives report sizeable share disposals.
Phibro Animal Health Corporation supplies animal health products and nutrition solutions for livestock markets worldwide. The company serves poultry, cattle, swine, and aquaculture producers across several regions. Its shares trade on the Nasdaq exchange under the ticker PAHC.
CEO Share Sale Draws Market Attention
The SEC Form 4 filing showed an indirect sale of 21,120 common shares. Bendheim completed the transactions through BFI Co. LLC during three trading sessions. The filing listed weighted average sale prices near $54.79 per share.
Records showed BFI Co. LLC held the shares sold in the transactions. Bendheim controls voting power and disposal authority over that entity. Regulators classified the transactions as indirect ownership sales.
After the reported sales, Bendheim retained 95,880 indirectly held shares. He also continued to hold 16,840 shares directly in his name. The filing showed continued ownership after the completed transactions.
Company Growth Supports Broader Story
Phibro Animal Health previously reported strong fiscal second-quarter financial results in February. Revenue rose 21% year over year to $373.9 million. Net income increased to $27.5 million from $3.2 million earlier.
Adjusted net income also advanced strongly during the reported quarter. The company linked growth to demand across several operating segments. Stronger product mix and volume also supported results.
In 2024, Phibro acquired Zoetis’ medicated feed additive business. That acquisition expanded product offerings and added new revenue streams. Recent company growth has reflected contributions from that business.
Guidance and Business Position Remain Key Factors
Phibro ends its fiscal year on June 30 each year. Management later raised fiscal 2026 guidance after stronger operating performance. The company now expects sales growth near 14% at the midpoint.
Management also projected net income growth near 86% at the midpoint. Those targets reflected stronger results across major business divisions. Animal health and nutrition demand remained central to company performance.
Phibro operates across North America, Latin America, Europe, and Asia. It sells antibacterials, vaccines, minerals, and nutritional additives. Tuesday trading focused on insider activity while company fundamentals remained part of the background.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
